Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2013;127:e283-e352.
Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med. 1996;335:1933-1940.
.Bigger JT; Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. N Engl J Med. 1997;337:1569-1575.
Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225-237.
Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140-2150.
Kalish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350:2151-2158.
Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877-883.
Hohnloser SH, Kuck KH, Dorian P, et al; DINAMIT Investigators. Prophylactic use of an implantable dioverter-defibrillator after acute myocardial infarction. N Engl J Med. 2004;351:2481-2488.
Moss AJ, Schuger C, Beck CA, et al; MADIT-RIT Trial Investigators. Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med. 2012;367:2275-2283.
Steinbeck G, Andresen D, Seidl K, et al; IRIS Investigators. Defibrillator implantation early after myocardial infarction. N Engl J Med. 2009:361:1427-1436.
Klein HU, Goldenberg I, Moss AJ. Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator. Eur Heart J. 2013;34:2230-2242.
Wilkoff BL, Williamson BD, Stern RS; PREPARE Study Investigators. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study. J Am Coll Cardiol. 2008;52:541-550.
Kutyifa V, et al. Results from the prospective registry of patients using the wearable defibrillator (WEARIT-II registry). Paper presented as a late breaking clinical trial at: European Society of Cardiology Congress 2014; August 30, 2014; Barcelona, Spain.

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Moderator(s)

Jagmeet P. Singh, MD, PhD

Associate Professor of Medicine, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts

Disclosures

Disclosure: Jagmeet P. Singh, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: BIOTRONIK; Boston Scientific; Medtronic, Inc.; St. Jude Medical; Sorin Group
Served as a speaker or a member of a speakers bureau for: Medtronic, Inc.; Sorin Group
Received grants for clinical research from: Boston Scientific; Medtronic, Inc.; St. Jude Medical; Sorin Group

Dr Singh does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Singh does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Panelist(s)

Jeanne Poole, MD

Director, Arrhythmia Service and Electrophysiology Laboratory, Division of Cardiology, University of Washington, Seattle, Washington

Disclosures

Disclosure: Jeanne Poole, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Boston Scientific; Physio-Control, Inc.
Served as a speaker or a member of a speakers bureau for: BIOTRONIK; Boston Scientific; Medtronic, Inc.
Received grants for clinical research from: National Heart, Lung, and Blood Institute; Sanofi
Owns stock, stock options, or bonds from: Cameron Health

Dr Poole does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Poole does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Ilan Goldenberg, MD

Professor of Cardiology; Director, Department of Cardiology, Heart Center, Sheba Medical Center, Tel Hashomer, Israel

Disclosures

Disclosure: Ilan Goldenberg, MD, has disclosed the following relevant financial relationships:
Received grants for clinical research from: Zoll Medical Corporation

Dr Goldenberg does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Goldenberg does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Valentina Kutyifa, MD, PhD

Research Assistant Professor, University of Rochester, Rochester, New York

Disclosures

Disclosure: Valentina Kutyifa, MD, PhD, has disclosed the following relevant financial relationships:
Received grants for clinical research from: Zoll Medical Corporation

Dr Kutyifa does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Kutyifa does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor(s)

George Boutsalis, PhD

Scientific Director, Medscape, LLC

Disclosures

Disclosure: George Boutsalis, PhD, has disclosed no relevant financial relationships.

Ronald K. Miller, PhD

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Ronald K. Miller, PhD, has disclosed no relevant financial relationships.

CME Reviewer(s)

Nafeez Zawahir, MD

CME Clinical Director, Medscape, LLC

Disclosures

Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

CME

Breaking Down WEARIT-II: Evaluating Outcomes in WCD Patients

Authors: Jagmeet P. Singh, MD, PhD; Ilan Goldenberg, MD; Jeanne Poole, MD; Valentina Kutyifa, MD, PhD
CME Released: 12/18/2014
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 12/18/2015, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This activity is intended for electrophysiologists, interventional cardiologists, cardiac surgeons, general cardiologists, internists, critical care specialists, cardiology nurses, and other allied healthcare professionals.

The goal of this activity is to update physicians on appropriate patient selection for treatment with implantable cardioverter defibrillators and the wearable cardioverter defibrillator based on clinical trial data.

Upon completion of this activity, participants will be able to:

Review data from major trials and registries thus far on the use of defibrillators in heart failure
Discuss WEARIT-II trial data, including efficacy outcomes and the implications of the data in clinical practice

Disclosures

Moderator(s)

Jagmeet P. Singh, MD, PhD

Associate Professor of Medicine, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts

Disclosures

Disclosure: Jagmeet P. Singh, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: BIOTRONIK; Boston Scientific; Medtronic, Inc.; St. Jude Medical; Sorin Group
Served as a speaker or a member of a speakers bureau for: Medtronic, Inc.; Sorin Group
Received grants for clinical research from: Boston Scientific; Medtronic, Inc.; St. Jude Medical; Sorin Group

Dr Singh does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Singh does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Panelist(s)

Jeanne Poole, MD

Director, Arrhythmia Service and Electrophysiology Laboratory, Division of Cardiology, University of Washington, Seattle, Washington

Disclosures

Disclosure: Jeanne Poole, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Boston Scientific; Physio-Control, Inc.
Served as a speaker or a member of a speakers bureau for: BIOTRONIK; Boston Scientific; Medtronic, Inc.
Received grants for clinical research from: National Heart, Lung, and Blood Institute; Sanofi
Owns stock, stock options, or bonds from: Cameron Health

Dr Poole does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Poole does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Ilan Goldenberg, MD

Professor of Cardiology; Director, Department of Cardiology, Heart Center, Sheba Medical Center, Tel Hashomer, Israel

Disclosures

Disclosure: Ilan Goldenberg, MD, has disclosed the following relevant financial relationships:
Received grants for clinical research from: Zoll Medical Corporation

Dr Goldenberg does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Goldenberg does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Valentina Kutyifa, MD, PhD

Research Assistant Professor, University of Rochester, Rochester, New York

Disclosures

Disclosure: Valentina Kutyifa, MD, PhD, has disclosed the following relevant financial relationships:
Received grants for clinical research from: Zoll Medical Corporation

Dr Kutyifa does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Kutyifa does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor(s)

George Boutsalis, PhD

Scientific Director, Medscape, LLC

Disclosures

Disclosure: George Boutsalis, PhD, has disclosed no relevant financial relationships.

Ronald K. Miller, PhD

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Ronald K. Miller, PhD, has disclosed no relevant financial relationships.

CME Reviewer(s)

Nafeez Zawahir, MD

CME Clinical Director, Medscape, LLC

Disclosures

Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

Accreditation Statements

For Physicians

Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

Strategies to Reduce the Risk for Sudden Cardiac Death

From Medscape Education Cardiology

CME

Breaking Down WEARIT-II: Evaluating Outcomes in WCD Patients

Authors: Jagmeet P. Singh, MD, PhD; Ilan Goldenberg, MD; Jeanne Poole, MD; Valentina Kutyifa, MD, PhDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME Released: 12/18/2014

Valid for credit through: 12/18/2015, 11:59 PM EST

processing....

This feature requires the newest version of Flash. You can download it here.

CME Information Download Slides

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.

The material presented here does not necessarily reflect the views of Medscape, LLC, or companies that support educational programming on medscape.org. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

References

Faculty and Disclosures

Moderator(s)

Jagmeet P. Singh, MD, PhD

Panelist(s)

Jeanne Poole, MD

Ilan Goldenberg, MD

Valentina Kutyifa, MD, PhD

Editor(s)

George Boutsalis, PhD

Ronald K. Miller, PhD

CME Reviewer(s)

Nafeez Zawahir, MD

CME

Breaking Down WEARIT-II: Evaluating Outcomes in WCD Patients

Target Audience and Goal Statement

Disclosures

Moderator(s)

Jagmeet P. Singh, MD, PhD

Panelist(s)

Jeanne Poole, MD

Ilan Goldenberg, MD

Valentina Kutyifa, MD, PhD

Editor(s)

George Boutsalis, PhD

Ronald K. Miller, PhD

CME Reviewer(s)

Nafeez Zawahir, MD

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Breaking Down WEARIT-II: Evaluating Outcomes in WCD Patients